LaserSight (US) moves forward in laser correction trials:
This article was originally published in Clinica
Executive Summary
LaserSight (US) has received FDA approval to proceed with Phase IIa clinical trials of its Compak-200 mini-excimer laser system for treatment of myopia. Trials will be performed at five locations in the US for corrections ranging from -1.5 to -10 dioptres.